Gene:
WFS1
Wolfram syndrome 1 (wolframin)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  DIDMOAD; WFS
PharmGKB Accession Id: PA37365

Details

Cytogenetic Location: chr4 : p16.1 - p16.1
GP mRNA Boundary: chr4 : 6271577 - 6304992
GP Gene Boundary: chr4 : 6261577 - 6307992
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to WFS1: 4

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The search for putative unifying genetic factors for components of the metabolic syndrome. Diabetologia. 2008. Sjögren M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical risk factors, DNA variants, and the development of type 2 diabetes. The New England journal of medicine. 2008. Lyssenko Valeriya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. American journal of human genetics. 2007. Amr Sami, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common variants in WFS1 confer risk of type 2 diabetes. Nature genetics. 2007. Sandhu Manjinder S, et al. PubMed

LinkOuts

UniProtKB:
WFS1_HUMAN (O76024)
Ensembl:
ENSG00000109501
GenAtlas:
WFS1
GeneCard:
WFS1
MutDB:
WFS1
ALFRED:
LO013024K
HuGE:
WFS1
Comparative Toxicogenomics Database:
7466
ModBase:
O76024
HumanCyc Gene:
HS03233
HGNC:
12762

Common Searches